levomethadone
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started May 7, 2015 (NCT04254731)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1- Mol. weight
- 309.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL159659 ↗
Also known as
- levomethadone
- levomethadone
- levomethadone
- levomethadone
- levomethadone
- levomethadone hcl
- levomethadone hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05251376 | Phase 1 | Feb 28, 2022 | Lyndra Inc., National Institute on Drug Abuse (NIDA) |
| NCT04254731 | Phase 4 | May 7, 2015 | University of Oslo |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lyndra Inc. | For profit | 1 | 1 | 1 | 2022 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2022 |
| University of Oslo | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1